RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Esophageal Cancer who are Treated without Surgery

Trial Profile

RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Esophageal Cancer who are Treated without Surgery

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2015

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Paclitaxel
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Feb 2014 Primary endpoint 'Overall-survival-rate' has not been met.
    • 18 Jan 2014 Results presented at the 2014 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top